Transgender Health (Adults)

Key points:

  • Everyone’s goals and transition wishes are different and individual. For example, not everyone wants hormones or surgery.

  • Transgender and non-binary people have often had previous negative healthcare experiences. Be kind and respectful and listen to your patients' needs.

  • Being transgender is not a mental health condition. Transgender people can make informed choices about their healthcare and their body if they have capacity to provide consent. Some may need additional mental health support for many reasons, including minority stress, experiences of stigma & discrimination, anxiety, depression and dysphoria.

  • Information on menstrual cessation options for transmasculine people can be found here.

  • Primary care gender affirming hormone therapy guidelines 2023 can be found here

  • In some areas in NZ pathways to access GAHT are moving towards informed consent primary care based prescribing. Interested GPs can join the trans health peer support group

  • Surgical transition options (other than genital surgery) vary by locality and access is often limited Genital surgery service

  • Fertility preservation options can be found here Transgender fertility

  • Gender affirming genital surgery is publicly funded and managed by the Ministry of Health.

  • Transgender (or trans) healthcare in NZ is guided by the Aotearoa Guidelines for Gender Affirming Health Care.

General Information

Gender Affirming Hormonal Therapy (GAHT)

Oestrogen-based (feminising) GAHT

Patients are prescribed a form of oestrogen and a testosterone blocker. The testosterone blocker is no longer needed if the patient has an orchiectomy. Effects, including timing and reversibility, can be found in the National Guidelines.

Oestrogen formulationUsual starting doseStandard doseComments
Oestradiol valerate (Progynova)1 - 2mg daily (dose usually increased gradually)4 - 6mg daily (max dose 6mg)
Oestradiol patch (Estradot)25 - 50mcg patch twice weekly (dose usually increased gradually)100-150mcg patch twice weekly (max 200mcg)Lower VTE risk Preferable if liver dysfunction
Testosterone BlockerDoseComments
Spironolactone100-200mg dailyMonitor potassium levels
Cyproterone12.5mg dailyUse lowest effective dose. Long term use of higher doses linked to meninigioma formation. Contraindicated if history of thromboembolism. Monitor LFT

Monitoring - check bloods & BP 3-6 monthly in the first year on hormones and 6-12 monthly thereafter

InvestigationComment
ElectrolytesIf on spironolactone
Liver Function TestsIf abnormal, recommend transdermal oestrogen first line and avoid cyproterone
Lipds
OestrogenOnly checked to ensure levels are not supraphysiological. Some guidelines would recommend an upper limit of 700-750 pmol/L26 but there is insufficient evidence to definitively recommend any target range. Experience suggests that oestrogen levels or dose do not correlate well with physical effects or self-reported satisfaction with E-GAHT, and exogenous oestrogen is not well measured in the serum.
TestosteroneOn cyproterone- level usually suppressed < 2nmol/L
On spironolactone- no need to measure as it doesn't usually suppress. Instead, spironolactone blocks the effect of T at the tissue.

Gender Affirming Hormonal Therapy (GAHT)

Testosterone-based (masculinising) GAHT

This involves using one form of testosterone (usually injections). Some people choose standard doses of testosterone and others opt for low dose testosterone. While low doses still result in all of the same permanent effects of standard dose testosterone, it may give the patient more control over the speed of the changes (although this cannot be guaranteed either). Effects, including timing and reversibility, can be found in the National Guidelines.

Monitoring - check bloods & BP 3-6 monthly in the first year on hormones and 6-12 monthly thereafter.

FormulationStandard DoseTiming of Blood testsNotes
Depo-testosterone200mg IM FornightlyMid-way between injectionsCan be self administered. Out of stock until Sept 2022
Sustanon (testosterone esters)250mg/ml IM every 3 weeksMid-way between injectionsCan be self administered
Reandron (testosterone undecylate)1000mg IM every 10-14 weeksJust prior to next injectionMust be given by health professional
Androderm (patches)7.5mg dailyIn the morningSkin irritation is common
InvestigationsComment
Complete Blood countIf haematocrit >0.54 reduce dose of testosterone and/or discuss with endocrine/haematology. (ensure you are using male reference range)
Liver function tests
Lipids
TestosteroneAim for normal male reference range (unless patient is on low dose testosterone in which case ensure it is above 5-6 nmol/L) Don’t check until patient has been on T for 6-9 months as levels take time to stabilise. After this time check 6-12 monthly. Timing of blood test is dependent on formulation used (see table above) If raised, reduce dose and repeat level in 3 months.

Additional resources

  • This Goodfellow MedCase covers the knowledge needed to prescribe maintenance GAHT (repeat prescriptions) and answers many common questions. Click here.

  • Advice on maintenance hormone prescribing can also be found here